Immunotherapy for Hodgkin’s Lymphoma: How It Works, Results and What to Expect

Immunotherapy for Hodgkin's lymphoma is a treatment that strengthens or redirects the immune system's ability to detect and destroy lymphoma cells. It is most often used for lymphoma that has returned after treatment or has not responded sufficiently to earlier therapies, although its role may differ depending on the individual treatment plan.

Overview: Immunotherapy for Hodgkin's Lymphoma

Immunotherapy for Hodgkin’s lymphoma uses medicines that help the body’s immune system identify and attack lymphoma cells. In classical Hodgkin lymphoma, the most widely used immunotherapies are immune checkpoint inhibitors, usually PD-1 inhibitors. They are commonly considered when the lymphoma has returned after prior treatment or has not responded as expected to chemotherapy and other standard approaches.

Hodgkin lymphoma is a cancer of the lymphatic system, a key part of immune function. Its abnormal cells can interfere with immune responses and may display proteins that switch off nearby immune cells. Checkpoint inhibitor therapy can block this escape mechanism, allowing T cells to recognize and respond to cancer cells more effectively. Treatment decisions are individualized and made by a hematologist-oncologist after reviewing the lymphoma type, stage, prior therapies, general health and personal goals.

For background on the disease, readers may find Hodgkin's lymphoma helpful. Immunotherapy may be used alone, in combination with other medicines, before or after stem cell transplantation, or as part of a clinical trial, depending on the clinical situation.

How Immunotherapy Works

Immune cells normally use checkpoints as safety signals. These signals help prevent excessive immune activity and reduce the risk of damage to healthy tissue. Classical Hodgkin lymphoma cells often exploit the PD-1 checkpoint pathway by producing proteins called PD-L1 and PD-L2. When these proteins connect with PD-1 receptors on T cells, the T cells may become less able to attack the lymphoma.

PD-1 inhibitors block this interaction. Rather than directly killing cancer cells in the way many chemotherapy medicines do, they help restore the immune system’s ability to recognize lymphoma cells. This mechanism is one reason checkpoint inhibitors can be effective in classical Hodgkin lymphoma, particularly after the disease has relapsed or proved refractory.

Not every form of lymphoma behaves in the same way. Immunotherapy choices, expected benefit and monitoring differ between classical Hodgkin lymphoma and other lymphomas. A specialist may also discuss antibody-drug conjugates, chemotherapy, radiation therapy, targeted treatment or stem cell transplantation as part of an overall plan.

Who May Be a Candidate?

Immunotherapy is most often considered for people with classical Hodgkin lymphoma that has relapsed, meaning it returned after treatment, or refractory lymphoma, meaning it did not respond adequately to treatment. It may be recommended after chemotherapy, after an autologous stem cell transplant, or when transplantation is not suitable. In selected cases, it may be incorporated earlier in treatment within a specialist-directed regimen.

Before recommending immunotherapy, the care team reviews biopsy results, imaging scans, previous medicines and treatment response. They also consider heart, lung, liver and kidney function; current infections; autoimmune conditions; pregnancy plans; and medicines that suppress the immune system. These factors do not always rule out immunotherapy, but they can change the balance of benefits and risks.

People with an organ transplant or significant autoimmune disease need especially careful assessment, because stimulating immune activity can potentially trigger organ rejection or worsen inflammatory illness. A multidisciplinary review can help coordinate care when lymphoma treatment intersects with other medical needs.

Depending on the treatment history, the specialist may also discuss stem cell transplantation as a potentially important part of treatment for relapsed Hodgkin lymphoma.

What Happens During Immunotherapy Treatment?

Before treatment begins, the oncology team explains the proposed medicine, treatment schedule, possible alternatives and likely side effects. Baseline testing commonly includes blood counts and tests of liver, kidney and thyroid function. Imaging, often with PET/CT or CT, helps establish the extent of lymphoma and provides a reference point for assessing response later.

Checkpoint inhibitor treatment is generally administered as an intravenous infusion in an outpatient infusion unit. The infusion itself may take a relatively short time, but the visit can be longer because of registration, assessments, medication preparation and observation. The schedule varies by medicine and treatment plan, often involving infusions every few weeks.

At each visit, patients are asked about new symptoms, including cough, breathlessness, diarrhea, rash, fatigue, headaches or changes in vision. Blood tests may be repeated before treatment. Follow-up scans are performed at planned intervals, although scan findings must be interpreted carefully because immune cells gathering around cancer tissue can sometimes temporarily resemble disease progression.

Patients should not stop treatment, skip appointments or take new prescription, over-the-counter or herbal products without discussing them with their oncology team. The primary treatment page immunotherapy provides further general information about how this approach is planned and monitored.

Benefits, Effectiveness and Possible Risks

How effective is immunotherapy for Hodgkin’s lymphoma?

Checkpoint inhibitors can produce meaningful responses in many people with relapsed or refractory classical Hodgkin lymphoma, including those whose disease has progressed after several previous treatments. Some people achieve a complete response, meaning no evidence of active lymphoma is seen on assessment, while others have a partial response or stable disease. The duration of benefit varies, and response rates from research studies cannot predict an individual outcome.

Immunotherapy may help control lymphoma, reduce symptoms and create an opportunity for other potentially curative treatments, such as transplantation, in appropriate patients. However, it may not work for everyone, and lymphoma can progress despite treatment. Ongoing assessment enables the care team to adjust the plan if needed.

Common side effects can include tiredness, itching or rash, nausea, reduced appetite, joint aches and infusion reactions. Unlike conventional chemotherapy, checkpoint inhibitors may cause immune-related side effects, in which activated immune cells inflame healthy organs. These can affect the skin, bowel, lungs, liver, hormone-producing glands, kidneys, nerves or other organs.

• New or worsening cough, chest pain or shortness of breath may indicate lung inflammation.
• Persistent diarrhea, abdominal pain or blood in stool may indicate bowel inflammation.
• Yellowing of the skin or eyes, dark urine, marked weakness, severe headache or unusual confusion requires urgent medical advice.

Many immune-related effects can be managed successfully, particularly when identified early. Patients should contact their oncology team promptly about new symptoms rather than waiting for the next appointment.

Living Safely During Treatment

What is not allowed during immunotherapy?

There is no universal list of prohibited activities or foods during immunotherapy. Most people can continue many everyday activities as their energy and medical condition allow. However, they should not start vitamins, herbal remedies, supplements, antibiotics, steroids or other medicines without checking with the oncology team, as some products may interact with treatment or complicate side-effect assessment.

It is important not to ignore symptoms or self-treat persistent diarrhea, fever, breathlessness, severe rash or unusual fatigue without medical guidance. Alcohol should be discussed with the treating clinician, particularly if liver tests are abnormal or medicines are being used that can affect the liver. Smoking and vaping are best avoided because they can worsen lung health and make respiratory symptoms more difficult to evaluate.

Patients should use reliable contraception if advised by their treatment team and should discuss pregnancy, breastfeeding or fertility preservation before treatment starts. Vaccinations should be reviewed with the oncology team; some vaccines may be appropriate, while live vaccines may not be recommended in particular circumstances. Good hand hygiene, a balanced diet, gentle physical activity and rest can support general wellbeing during care.

Emotional support is also important. Anxiety, disrupted routines and uncertainty are common during cancer treatment. Support from relatives, counseling services, patient organizations and the cancer care team can help people manage practical and emotional concerns.

Outlook, Cure and Long-Term Follow-Up

Do you ever get rid of Hodgkin’s lymphoma?

Yes. Many people with Hodgkin lymphoma are cured, particularly when it is diagnosed and treated at an earlier stage. Even when lymphoma returns after initial treatment, further therapy can sometimes achieve long-term remission or cure. The likelihood depends on factors such as lymphoma subtype, stage, response to first treatment, time to relapse and overall health.

Complete remission means there are no detectable signs of active lymphoma after treatment. It is an encouraging result, but regular follow-up remains important because relapse can occur and some cancer treatments may have delayed effects. Follow-up appointments may include symptom review, physical examination, blood tests and imaging when clinically needed.

What is the 5-year survival rate for people with Hodgkin’s lymphoma?

Population-based cancer statistics show that Hodgkin lymphoma has a high overall five-year relative survival rate in many countries, often close to or above 85% in large national datasets. This figure combines people of different ages, stages, lymphoma subtypes and treatment eras, so it cannot estimate the outlook for one person.

Survival is generally better for localized disease than for advanced disease, but modern treatments have improved outcomes across many groups. A hematologist-oncologist can offer a more individualized discussion after reviewing staging results and the response to treatment. Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals support diagnosis and treatment planning for international patients with Hodgkin lymphoma.

When to Seek Medical Care

Anyone receiving immunotherapy should contact their oncology team promptly if they develop a new or worsening cough, shortness of breath, chest pain, persistent diarrhea, severe abdominal pain, fever, significant rash, yellowing of the skin or eyes, severe weakness, confusion, severe headache or major changes in vision. These symptoms do not always mean a serious reaction, but they should be assessed without delay.

Emergency medical care is appropriate for severe breathing difficulty, chest pain, fainting, signs of a severe allergic reaction, uncontrolled bleeding or sudden confusion. If emergency care is needed, patients should tell clinicians that they are receiving immunotherapy and provide the name of the medicine if possible.

People who notice painless swollen lymph nodes, unexplained persistent fever, drenching night sweats, unintentional weight loss, persistent itching or unusual fatigue should arrange a medical assessment. These symptoms can have many causes, but timely evaluation is important.

Frequently asked questions

Is immunotherapy the same as chemotherapy for Hodgkin's lymphoma?

No. Chemotherapy directly targets rapidly dividing cells, while immunotherapy helps the immune system recognize and attack cancer cells. Both may be used at different points in Hodgkin lymphoma treatment, sometimes as part of a broader treatment strategy.

How long does immunotherapy for Hodgkin's lymphoma last?

The duration depends on the medicine used, treatment response, side effects and the overall treatment goal. Infusions are commonly given every few weeks, with regular reviews to decide whether treatment should continue, pause or change.

Can immunotherapy cure relapsed Hodgkin's lymphoma?

Immunotherapy can achieve deep and sometimes durable responses in relapsed or refractory classical Hodgkin lymphoma. For some people, it may also help make a later potentially curative treatment, such as stem cell transplantation, possible. Individual outcomes vary.

Will immunotherapy make me lose my hair?

Hair loss is less common with checkpoint inhibitor immunotherapy than with many chemotherapy regimens. However, hair changes can occur for other reasons, including previous or combined treatments, hormonal changes or illness. The oncology team can explain what is most likely with a specific treatment plan.

Can I work or travel while receiving immunotherapy?

Many people can work or travel during treatment if they feel well enough and their care team agrees. Plans should account for infusion appointments, blood tests, access to medical care and the possibility of side effects. International travel should be discussed before booking.

What should I tell my doctor before starting immunotherapy?

Patients should report any autoimmune disease, organ transplant, lung or liver condition, infection, pregnancy plans and all medicines or supplements they use. This information helps the care team assess safety and arrange appropriate monitoring.

References

• National Cancer Institute
• American Cancer Society
• National Comprehensive Cancer Network
• Leukemia & Lymphoma Society
• European Society for Medical Oncology

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.